His most globally cited work, titled “Amyotrophic Lateral Sclerosis” published in The Lancet (TGCS = 1,718), proposed the potential of the SOD1 gene as a presymptomatic biomarker and evaluated therapeutic strategies, including riluzole, symptomatic supportive medications (muscle relaxants, anticonvulsants, anticholinergic antidepressants, analgesics), and investigational agents such as insulin-like growth factor-1, lithium carbonate, minocycline, and stem-cell therapy. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.